{
    "id": 2929,
    "fullName": "RAD51C loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RAD51C loss indicates loss of the RAD51C gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5889,
        "geneSymbol": "RAD51C",
        "terms": [
            "RAD51C",
            "BROVCA3",
            "FANCO",
            "R51H3",
            "RAD51L2"
        ]
    },
    "variant": "loss",
    "createDate": "01/12/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1611,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAD51C-deficient gastric cancer cells demonstrated increased sensitivity to Lynparza (olaparib) compared to cells over expressing RAD51C, and Lynparza (olaparib) treatment inhibited tumor growth in RAD51C-deficient gastric cancer cell line xenograft models (PMID: 23512992).",
            "molecularProfile": {
                "id": 2751,
                "profileName": "RAD51C loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1652,
                    "pubMedId": 23512992,
                    "title": "RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23512992"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2751,
            "profileName": "RAD51C loss",
            "profileTreatmentApproaches": [
                {
                    "id": 4369,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "RAD51C loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}